2011
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma. Journal Of Clinical Investigation 2011, 121: 1313-1328. PMID: 21436589, PMCID: PMC3070607, DOI: 10.1172/jci42405.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedApoptosisBevacizumabCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsGene Expression ProfilingHumansLung NeoplasmsMaleMiceMice, NudeNeovascularization, PathologicRNA, MessengerRNA, NeoplasmStromal CellsUp-RegulationVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Xenograft Model Antitumor AssaysConceptsMouse xenograft modelHuman lung adenocarcinomaTumor cellsPrimary resistanceLung adenocarcinomaXenograft modelFGFR pathwayProgression-free survivalVEGF inhibitor bevacizumabEndothelium of tumorsInhibitors of angiogenesisCombination regimensTreatment of cancerVEGF inhibitorsPericyte coverageAntiangiogenic therapyVascular remodelingAngiogenesis inhibitorsTherapeutic efficacyTumor growthStromal pathwaysClinical useEGFRAcquired ResistanceEGFR pathwayImaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets, Complementary/Innovative Treatment, and Therapeutic Modalities
Hong W, Herbst R. Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets, Complementary/Innovative Treatment, and Therapeutic Modalities. 2011 DOI: 10.21236/ada548594.Peer-Reviewed Original ResearchRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayLung cancerTherapeutic modalitiesNSCLC pathogenesisEGFR pathwayInnovative treatmentsMolecular targetsERK pathwaySignal transduction pathwaysImaging techniquesModalitiesPathwayTransduction pathwaysPeptide approachPatientsPathogenesisCancerReceptors
2010
IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities). 2010 DOI: 10.21236/ada525846.Peer-Reviewed Original Research
2009
IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2009 DOI: 10.21236/ada504658.Peer-Reviewed Original Research
2008
IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2008 DOI: 10.21236/ada483184.Peer-Reviewed Original ResearchMalignant pleural effusionRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayAdvanced diseasePleural effusionLung cancerNSCLC pathogenesisMolecular therapyEGFR pathwayERK pathwayCD-ROM programSignal transduction pathwaysImaging techniquesPathwayTransduction pathwaysPeptide approachPulmonologistsEffusionPathogenesisTherapyCancerDiseasePreventionReceptorsIMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2008 DOI: 10.21236/ada486510.Peer-Reviewed Original ResearchMalignant pleural effusionRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayAdvanced diseasePleural effusionLung cancerNSCLC pathogenesisMolecular therapyEGFR pathwayERK pathwayCD-ROM programSignal transduction pathwaysImaging techniquesPathwayTransduction pathwaysPulmonologistsEffusionPathogenesisTherapyCancerDiseasePreventionReceptors
2002
The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma
Waxman ES, Herbst RS. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Seminars In Oncology Nursing 2002, 18: 20-29. PMID: 12053861, DOI: 10.1053/sonu.2002.33072.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorColorectal carcinomaGrowth factor receptorClinical experienceAnti-EGFR monoclonal antibodiesTraditional cytotoxic approachesFactor receptorExtensive clinical testingTyrosine kinase inhibitorsEarly clinical experienceVariety of tumorsSignificant antitumor activityBiological agentsTreatment of cancerCytotoxic approachesEGFR resultsClinical testingNursing practiceCarcinomaMonoclonal antibodiesEGFR pathwayKinase inhibitorsAntitumor activityVariety of mechanismsReceptors